Pressmeddelande

Inhalation Research Services receives revised order with increased payment from US pharma company

Cision Publicerad: 18 Oct 2022 08:29

(Stockholm 18 October 2022) Inhalation Research Services (IRS) has received a revised order increasing the amount that it will be paid by a US pharma company. The original order, communicated on 18 July 2022, was for 136,000 Euro. This has now been raised to 151,000 Euro as additional steps within the research project have been contracted out to IRS by the client.

ISAB’s world-class expertise in inhalation, and its high-precision IPL (Isolated Perfused Lung) ex vivo method, were decisive in the client’s choice of IRS for research into a new repurposed drug being reformulated for administration via the lungs.

ISAB CEO Manoush Masarrat: “We are pleased with the confidence our client has shown in Inhalation Research Services and our technology.”

Bifogade filer

ISAB CRO revised order_PRMM.final docxhttps://mb.cision.com/Main/15842/3650048/1640058.pdf

Nyheter om Inhalation Sciences

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!